Please ensure Javascript is enabled for purposes of website accessibility

Are Chloroquine and Hydrochloroquine Approved to Treat COVID-19?

By Brian Orelli, PhD - Mar 20, 2020 at 7:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

No, but doctors can still use the drugs despite limited evidence of their effectiveness.

Despite what President Donald Trump said at a White House briefing on Thursday, the Food and Drug Administration (FDA) hasn't approved chloroquine and its less-potent-but-safer offspring, hydrochloroquine, to treat COVID-19, the disease caused by the new coronavirus.

"Normally the FDA would take a long time to approve something like that, and it's -- it was approved very, very quickly and it's now approved, by prescription," Trump said.

Neither chloroquine nor hydrochloroquine are approved by the FDA to treat COVID-19, but they are approved to treat malaria -- and have been for decades. Hydrochloroquine is also used to treat lupus and rheumatoid arthritis since it has anti-inflammatory properties.

For most medications, the FDA gives doctors leeway to prescribe drugs for whatever disease they think the drug will help. So-called off-label prescriptions can allow sales to ramp up between when new clinical trial results are presented at medical meetings and when the FDA finally approves the expanded indication months later.

Patient and doctors in protective suits in a restricted area

Image source: Getty Images.

Unfortunately, there's minimal evidence to suggest that the two drugs help patients with COVID-19. Scientists in China have shown the drugs can inhibit growth of the coronavirus that causes COVID-19 in cells grown in a laboratory.

Doctors in France have reportedly tested hydroxychloroquine on 24 patients. It showed that patients treated with the drug plus the antibiotic azithromycin reduced the amount of virus in the patients, but larger studies with control groups will be required to know for sure if chloroquine or hydrochloroquine actually helps patients.

"We want to do that in the setting of a clinical trial -- a large, pragmatic clinical trial -- to actually gather that information and answer the question that needs to be answered and -- asked and answered," FDA commissioner Stephen Hahn said at the conference.

Multiple drugmakers, including Bayer (BAYR.Y -0.97%), Teva Pharmaceutical (TEVA 0.91%), and Novartis (NVS 3.63%) have committed to donating chloroquine or hydrochloroquine tablets. And Mylan (MYL) and Amneal Pharmaceuticals (AMRX -2.44%) plan to ramp up production of hydroxychloroquine.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novartis AG Stock Quote
Novartis AG
NVS
$84.83 (3.63%) $2.97
Viatris Inc. Stock Quote
Viatris Inc.
MYL
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.74 (0.91%) $0.07
Bayer Stock Quote
Bayer
BAYR.Y
$15.23 (-0.97%) $0.15
Amneal Pharmaceuticals, Inc. Stock Quote
Amneal Pharmaceuticals, Inc.
AMRX
$3.20 (-2.44%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.